Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

Blood

Volumn 99, Issue 11, 2002, Pages 3916-3922

  Einsele, Hermann ^a,b,c,d,e   Roosnek, Eddy ^a,b,c,d,e   Rufer, Nathalie ^a,b,c,d,e   Sinzger, Christian ^a,b,c,d,e   Riegler, Susanne ^a,b,c,d,e   Löffler, Jürgen ^a,b,c,d,e   Grigoleit, Ulrich ^a,b,c,d,e   Moris, Arnaud ^a,b,c,d,e   Rammensee, Hans Georg ^a,b,c,d,e   Kanz, Lothar ^a,b,c,d,e   Kleihauer, Annette ^a,b,c,d,e   Frank, Friederike ^a,b,c,d,e   Jahn, Gerhard ^a,b,c,d,e   Hebart, Holger ^a,b,c,d,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c National Center of Competence in Research in Molecular Oncology   (Switzerland)

^d Abteilung Medizinische Virologie und Epidemiologie der Viruskrankheiten   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HLA ANTIGEN; VIRUS ANTIGEN;

ADULT; ALLOIMMUNITY; ARTICLE; CELL TRANSFER; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; VIRUS LOAD;

EID: 0036624737     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.3916     Document Type: Article

References (27)

1. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
2. Krause H, Hebart H, Jahn G, Müller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111-1116.
3. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Ridell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83;1971-1979.
4. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive antiviral therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-763.
5. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997;176:782-785.
6. Quinnan GV, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982;307:7-13.
7. Borysiewicz LK, Graham S, Hickling JK, Mason PD, Sissons JG. Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol. 1988;18:269-275.
8. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373-1380.
9. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viraemia and specific T-helper cell response as predictors of disease after allogeneic marrow transplantation. Br J Haematol. 1993;83:118-124.
10. Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediateearly antigens mediate protective immunity. J Virol. 1987;61:3102-3108.
11. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat EpsteinBarr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
12. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996;18:347-353.
13. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virusspecific T lymphocytes. Nat Med. 1996;2:551-555.
14. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
15. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
16. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
17. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions. Blood. 2001;97:994-1000.
18. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8(+) T lymphocytes in T-celldepleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98:1358-1364.
19. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
20. Liungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA, eds. Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Paris, France: Elsevier Science Publisher B.V.; 1993;233-237.
21. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood. 1996;88:4063-4071.
22. Einsele H, Steidle H, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood. 1991;77:1104-1110.
23. Einsele H, Ehninger G, Steidle M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirds disease. Lancet. 1991;338:1170-1172.
24. Altman JD, Moss PAH, Goulder PR, et al. Phenotypic analysis of antigen specific T lymphocytes. Science. 1996;274:94-96.
25. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol. 2001;113:231-239.
26. Rentenaar RJ, Gamadia LE, van DerHoek N, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest. 2000;105:541-548.
27. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398.